Login / Signup

Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.

Xiaoyan LuJames JarrettSusannah SadlerMin TanJames DennisVipul Jairath
Published in: International journal of clinical pharmacy (2022)
The current treatment landscape benefits patients with moderately to severely active UC, improving key outcomes; filgotinib 200 mg was similar to current standard of care in most outcomes.
Keyphrases
  • rheumatoid arthritis
  • ulcerative colitis
  • healthcare
  • palliative care
  • metabolic syndrome
  • pain management
  • skeletal muscle
  • glycemic control
  • health insurance
  • affordable care act